Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2620
Revised: July 15, 2024
Accepted: July 22, 2024
Published online: August 27, 2024
Processing time: 60 Days and 3.6 Hours
Acute non-variceal upper gastrointestinal bleeding (ANVUGIB) represents a sig
To assess the prognostic value of the Rockall risk score in a Chinese cohort of patients with ANVUGIB.
A retrospective analysis of 168 ANVUGIB patients’ medical records was condu
Significant associations were found between the Rockall score and various clinical outcomes. High Rockall scores were significantly associated with rebleeding events (r = 0.735, R2 = 0.541, P < 0.001) and strongly positively correlated with adverse outcomes. Low hemoglobin levels (t = 2.843, P = 0.005), high international normalized ratio (t = 3.710, P < 0.001), active bleeding during endoscopy (χ2 = 7.950, P = 0.005), large ulcer size (t = 6.348, P < 0.001), and requiring blood transfusion (χ2 = 6.381, P = 0.012) were all significantly associated with rebleeding events. Furthermore, differences in treatment and management strategies were identified between patients with and without rebleeding events. ROC analysis indicated the excellent discriminative power (sensitivity: 0.914; specificity: 0.816; area under the curve: 0.933; Youden index: 0.730) of the Rockall score in predicting rebleeding events within 3 months.
This study provides valuable insights into the prognostic value of the Rockall risk score for ANVUGIB in the Chinese population. The results underscore the potential of the Rockall score as an effective tool for risk stratification and prognostication, with implications for guiding risk-appropriate management strategies and optimizing care for patients with ANVUGIB.
Core Tip: This retrospective clinical study aimed to assess the prognostic value of the Rockall risk score in a Chinese cohort of patients with acute non-variceal upper gastrointestinal bleeding (ANVUGIB). The conclusion of this study provides valuable insights into the prognostic value of the Rockall risk score for ANVUGIB in the Chinese population. The results underscore the potential of the Rockall score as an effective tool for risk stratification and prognostication, with implications for guiding risk-appropriate management strategies and optimizing care for patients with ANVUGIB.
